secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023740
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations
--------------------------------------------------------------------------------

- Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.
- Loss from operations improved to $1.3M in Q2 2025 versus $1.4M in the prior year quarter.
- Raised $2.4M net in April and June 2025 from sale of senior subordinated notes and warrants to Aditxt (ADTX).
- PHEXXI submitted for UAE marketing approval by licensee Pharma 1; SOLOSEC submission expected Q3 2025.
- Net loss per share was $(0.02) in Q2 2025 vs net income of $0.02 per share in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/0001641172-25-023740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer